Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation
© 2021. The American Society for Experimental NeuroTherapeutics, Inc..
Prion diseases are caused by the propagation of PrPSc, the pathological conformation of the PrPC prion protein. The molecular mechanisms underlying PrPSc propagation are still unsolved and no therapeutic solution is currently available. We thus sought to identify new anti-prion molecules and found that flunarizine inhibited PrPSc propagation in cell culture and significantly prolonged survival of prion-infected mice. Using an in silico therapeutic repositioning approach based on similarities with flunarizine chemical structure, we tested azelastine, duloxetine, ebastine, loperamide and metixene and showed that they all have an anti-prion activity. Like flunarizine, these marketed drugs reduced PrPSc propagation in cell culture and in mouse cerebellum organotypic slice culture, and inhibited the protein folding activity of the ribosome (PFAR). Strikingly, some of these drugs were also able to alleviate phenotypes due to PABPN1 nuclear aggregation in cell and Drosophila models of oculopharyngeal muscular dystrophy (OPMD). These data emphasize the therapeutic potential of anti-PFAR drugs for neurodegenerative and neuromuscular proteinopathies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 18(2021), 2 vom: 31. Apr., Seite 1137-1150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bamia, Aline [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 04.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13311-020-00992-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320938522 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320938522 | ||
| 003 | DE-627 | ||
| 005 | 20240204231912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13311-020-00992-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1280.xml |
| 035 | |a (DE-627)NLM320938522 | ||
| 035 | |a (NLM)33533011 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bamia, Aline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 04.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The American Society for Experimental NeuroTherapeutics, Inc. | ||
| 520 | |a Prion diseases are caused by the propagation of PrPSc, the pathological conformation of the PrPC prion protein. The molecular mechanisms underlying PrPSc propagation are still unsolved and no therapeutic solution is currently available. We thus sought to identify new anti-prion molecules and found that flunarizine inhibited PrPSc propagation in cell culture and significantly prolonged survival of prion-infected mice. Using an in silico therapeutic repositioning approach based on similarities with flunarizine chemical structure, we tested azelastine, duloxetine, ebastine, loperamide and metixene and showed that they all have an anti-prion activity. Like flunarizine, these marketed drugs reduced PrPSc propagation in cell culture and in mouse cerebellum organotypic slice culture, and inhibited the protein folding activity of the ribosome (PFAR). Strikingly, some of these drugs were also able to alleviate phenotypes due to PABPN1 nuclear aggregation in cell and Drosophila models of oculopharyngeal muscular dystrophy (OPMD). These data emphasize the therapeutic potential of anti-PFAR drugs for neurodegenerative and neuromuscular proteinopathies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a OPMD | |
| 650 | 4 | |a PABPN1 | |
| 650 | 4 | |a PFAR | |
| 650 | 4 | |a PrPSc | |
| 650 | 4 | |a Prions | |
| 650 | 4 | |a drug repositioning | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 650 | 7 | |a PABPN1 protein, mouse |2 NLM | |
| 650 | 7 | |a Poly(A)-Binding Protein I |2 NLM | |
| 650 | 7 | |a Prion Proteins |2 NLM | |
| 650 | 7 | |a Protein Aggregates |2 NLM | |
| 650 | 7 | |a Flunarizine |2 NLM | |
| 650 | 7 | |a R7PLA2DM0J |2 NLM | |
| 700 | 1 | |a Sinane, Maha |e verfasserin |4 aut | |
| 700 | 1 | |a Naït-Saïdi, Rima |e verfasserin |4 aut | |
| 700 | 1 | |a Dhiab, Jamila |e verfasserin |4 aut | |
| 700 | 1 | |a Keruzoré, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Phu Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Bertho, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Soubigou, Flavie |e verfasserin |4 aut | |
| 700 | 1 | |a Halliez, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Blondel, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Trollet, Capucine |e verfasserin |4 aut | |
| 700 | 1 | |a Simonelig, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Friocourt, Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Béringue, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Bihel, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Voisset, Cécile |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |d 2007 |g 18(2021), 2 vom: 31. Apr., Seite 1137-1150 |w (DE-627)NLM167471872 |x 1878-7479 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2021 |g number:2 |g day:31 |g month:04 |g pages:1137-1150 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13311-020-00992-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2021 |e 2 |b 31 |c 04 |h 1137-1150 | ||